Harvard Bioscience
HBIO
74 hedge funds and large institutions have $84.8M invested in Harvard Bioscience in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
7% more capital invested
Capital invested by funds: $78.9M → $84.8M (+$5.91M)
5% less call options, than puts
Call options by funds: $19K | Put options by funds: $20K
4% less funds holding
Funds holding: 77 → 74 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$4.38M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$1.71M |
| 3 |
KAM
Knightsbridge Asset Management
Newport Beach,
California
|
+$930K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$667K |
| 5 |
Renaissance Technologies
New York
|
+$434K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.24M |
| 2 |
FCAM
F&C Asset Management
Edinburgh, Scotland,
United Kingdom
|
-$1.63M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$182K |
| 4 |
CSM
Central Square Management
Naperville,
Illinois
|
-$150K |
| 5 |
Morgan Stanley
New York
|
-$129K |
HBIO Hedge Fund Activity: Q1 2014 in Review
74 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2014, worth a combined $84.8M — up 7.5% from $78.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of HBIO and 6 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 27 added.
The largest buyer was First Light Asset Management, opening a new position worth an estimated $4.38M. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $2.24M sold.
- 74 institutional investors held Harvard Bioscience (HBIO) as of Q1 2014, down from 77 in Q4 2013.
- Funds reported $84.8M of Harvard Bioscience stock for Q1 2014, up 7.5% quarter-over-quarter.
- 6 funds opened new Harvard Bioscience positions in Q1 2014 and 9 closed out, a net change of -3 holders.
- The largest Harvard Bioscience buyer in Q1 2014 was First Light Asset Management, an estimated $4.38M added.
- The largest Harvard Bioscience seller in Q1 2014 was Fuller & Thaler Asset Management, an estimated $2.24M sold.
Based on aggregated 13F filings for Q1 2014.